Cytovance Biologics, Inc. – Trademark Portfolio
Entity Type: 03
Cytovance Biologics, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include CYTOVANCE and KEYSTONE EXPRESSION SYSTEM. The owner is based in Oklahoma City, OK.
Suite 200
800 Research Parkway
Oklahoma City, OK 73104
Showing of trademarks Trademarks
Trademark Classifications
Cytovance Biologics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Cytovance Biologics, Inc. have?
Cytovance Biologics, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.
What trademark classes does Cytovance Biologics, Inc. file in?
Cytovance Biologics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Cytovance Biologics, Inc.'s most well-known trademarks?
Cytovance Biologics, Inc.'s registered trademark portfolio includes well-known marks such as CYTOVANCE and KEYSTONE EXPRESSION SYSTEM. These are among 2 currently registered trademarks in the portfolio.
What is Cytovance Biologics, Inc.'s trademark registration success rate?
Cytovance Biologics, Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.